Business
Nurix Therapeutics Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607
NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types The ILAP aims to accelerate the time to market for
About this update from Nurix Therapeutics, Inc.
[{"type":"text","content":"NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types The ILAP aims to accelerate the time to market for innovative medicines that address the needs of patients with life-threatening or seriously debilitating diseases SAN FRANCISCO, March 29, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the innovative medicine designation, the Innovation Passport, for NX-1607 in the treatment of patients with advanced solid tumors. Nurix plans to present the initial pharmacokinetic and pharmacodynamic data from the NX-1607 Phase 1a study in mid-2022. “Receiving the Innovation Passport designation is an important step in Nurix’s regulatory strategy and in the development of NX-1607 with the potential to accelerate development of this novel small molecule as a new treatment option for patients with solid tumors,” said Robert J. Brown, M.D., executive vice president of clinical development of Nurix. “Notably, the Innovation Passport opens access to the Innovative Licensing and Access Pathway which facilitates a product-specific structure for regulatory and development milestones, frequent interactions with the review staff at the MHRA and its partner agencies to discuss the drug’s development, as well as reimbursement.” To receive the designation, an experimental therapy must meet three criteria: (1) the condition is life-threatening or seriously debilitating; (2) the program is an innovative medicine, clinically significant new indication or, it is intended for a special population; and (3) the medicine has the potential to offer benefits to patients. The Innovation Passport is awarded by the UK’s Innovation Licensing and Access Pathway Steering Group, which consists of representatives from the MHRA, the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), the All Wales Therapeutics and Toxicology Centre (AWTTC), and representatives from the ILAP Patient and Public Reference Group. The Innovation Passport is the entry point to the ILAP. The ILAP aims to accelerate the time to market and facilitate patient access to medicines through the development of a target...